肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）

2024-04-12 欧洲泌尿外科学会 EAU官网 发表于河南省

非肌层浸润性膀胱癌

本文为最新欧洲泌尿外科协会(EAU)非肌肉浸润性膀胱癌(NMIBC)、TaT1和原位癌(CIS)指南，主要目的是NMIBC的临床管理提供实用的建议。

中文标题：

2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）

英文标题：

EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

发布机构：

欧洲泌尿外科学会

发布日期：

2024-04-12

简要介绍：

本文为最新欧洲泌尿外科协会(EAU)非肌肉浸润性膀胱癌(NMIBC)、TaT1和原位癌(CIS)指南，主要目的是NMIBC的临床管理提供实用的建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f44d31c003e20725, title=2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）, enTitle=EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS), guiderFrom=EAU官网, authorId=0, author=, summary=本文为最新欧洲泌尿外科协会(EAU)非肌肉浸润性膀胱癌(NMIBC)、TaT1和原位癌(CIS)指南，主要目的是NMIBC的临床管理提供实用的建议。, cover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, journalId=0, articlesId=null, associationId=183, associationName=欧洲泌尿外科学会, associationIntro=成立于1973年，在欧洲泌尿外科的实践、研究、教育方面具有领导地位。已有超过16000名医疗人员加入其中。提供很多泌尿外科疾病的指南，更新较快。, copyright=0, guiderPublishedTime=Fri Apr 12 00:00:00 CST 2024, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;">本文为最新欧洲泌尿外科协会(EAU)非肌肉浸润性膀胱癌(NMIBC)、TaT1和原位癌(CIS)指南，主要目的是NMIBC的临床管理提供实用的建议。</div> </div>, tagList=[TagDto(tagId=34797, tagName=非肌层浸润性膀胱癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100)], articleKeywordId=34797, articleKeyword=非肌层浸润性膀胱癌, articleKeywordNum=6, guiderKeywordId=34797, guiderKeyword=非肌层浸润性膀胱癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2603, appHits=66, showAppHits=0, pcHits=594, showPcHits=2537, likes=0, shares=10, comments=6, approvalStatus=1, publishedTime=Sat May 04 16:14:00 CST 2024, publishedTimeString=2024-04-12, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu May 02 13:43:52 CST 2024, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Fri May 03 07:09:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=河南省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）.pdf)])
2024 EAU指南：非肌层浸润性膀胱癌（TaT1和CIS）.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2211826, encodeId=a698221182668, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b389364288, createdName=ms5000001448983807, createdTime=Wed Jun 26 20:34:22 CST 2024, time=2024-06-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208545, encodeId=e0c822085459b, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:37:34 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208544, encodeId=048d2208544e4, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:36:17 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2201713, encodeId=fb652201e1351, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=da249285458, createdName=ms3000001725584491, createdTime=Sat May 04 16:37:01 CST 2024, time=2024-05-04, status=1, ipAttribution=天津)]
    2024-06-26 ms5000001448983807 来自四川省

    我要积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2211826, encodeId=a698221182668, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b389364288, createdName=ms5000001448983807, createdTime=Wed Jun 26 20:34:22 CST 2024, time=2024-06-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208545, encodeId=e0c822085459b, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:37:34 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208544, encodeId=048d2208544e4, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:36:17 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2201713, encodeId=fb652201e1351, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=da249285458, createdName=ms3000001725584491, createdTime=Sat May 04 16:37:01 CST 2024, time=2024-05-04, status=1, ipAttribution=天津)]
    2024-06-06 ms4000000599390769 来自上海

    我要积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2211826, encodeId=a698221182668, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b389364288, createdName=ms5000001448983807, createdTime=Wed Jun 26 20:34:22 CST 2024, time=2024-06-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208545, encodeId=e0c822085459b, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:37:34 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208544, encodeId=048d2208544e4, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:36:17 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2201713, encodeId=fb652201e1351, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=da249285458, createdName=ms3000001725584491, createdTime=Sat May 04 16:37:01 CST 2024, time=2024-05-04, status=1, ipAttribution=天津)]
    2024-06-06 ms4000000599390769 来自上海

    我要积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2211826, encodeId=a698221182668, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b389364288, createdName=ms5000001448983807, createdTime=Wed Jun 26 20:34:22 CST 2024, time=2024-06-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208545, encodeId=e0c822085459b, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:37:34 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2208544, encodeId=048d2208544e4, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6129335121, createdName=ms4000000599390769, createdTime=Thu Jun 06 02:36:17 CST 2024, time=2024-06-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2201713, encodeId=fb652201e1351, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=da249285458, createdName=ms3000001725584491, createdTime=Sat May 04 16:37:01 CST 2024, time=2024-05-04, status=1, ipAttribution=天津)]
    2024-05-04 ms3000001725584491 来自天津

    我要积分

    0

相关指南

2022 EAU指南：非肌层浸润性膀胱癌（Ta，T1和CIS）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2022-03-05

2021 EAU指南：非肌层浸润性膀胱癌（Ta，T1和CIS）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2021-09-09

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018年标准版）

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-07-30

非肌层浸润性膀胱癌膀胱灌注治疗专家共识

中国泌尿外科相关专家组（统称） · 2019-01-30

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018简化版）

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-01-01

非肌层浸润性膀胱癌二次电切中国专家共识

中华医学会泌尿外科学分会(CUA) · 2017-08-30

拓展阅读

BJU Int.：欧洲多中心队列非肌层浸润性膀胱癌的真实世界复发率与进展率

在欧洲六家医疗中心的当代NMIBC患者队列中，HR/VHR组NMIBC患者面临显著更高的高级别复发和进展风险，表明在需要个体化治疗策略的同时，坚持足疗程膀胱灌注治疗对优化肿瘤学结果至关重要。

World J Urol：六种新型非肌层浸润性膀胱癌生物标志物在预测经尿道膀胱肿瘤电切术后复发情况

独评估的生物标志物在预测TURB后结局的预后能力方面表现不佳。更复杂的多变量预测模型可能会提高其预后性能。

Eur Urol Focus：根治性膀胱切除术与膀胱保留治疗在不同分期膀胱内灌注卡介苗无应答高危非肌层浸润性膀胱癌中的选择考量

与Ta或CIS相比，T1疾病的存在通常与更差的肿瘤学结局相关。在与CIS进行比较时，T1和Ta不应被归为一组。根治性膀胱全切术似乎主要由CIS的存在所驱动。

Eur Urol Oncol：二甲双胍对非肌层浸润性膀胱癌患者长期生存结局的影响

在接受BCG治疗的NMIBC患者中，以二甲双胍为基础的降糖治疗是RFS的独立风险因素。而使用非二甲双胍的降糖药物治疗与长期生存结局无关。

Eur Urol Oncol：对于卡介苗无应答的非肌层浸润性膀胱癌患者，膀胱内序贯灌注吉西他滨和多西他赛可降低疾病进展率

对于BCG无应答的NMIBC患者，若其拒绝或不适合进行膀胱全切术，膀胱内gem/doce与额外的BCG治疗相比，可降低疾病进展率。

World J Urol：TaHG非肌层浸润性膀胱癌患者中进行二次经尿道膀胱肿瘤电切术的作用

reTURBT在减少TaHG NMIBC患者复发方面显示出有效性，但其对疾病进展的影响仍不确定。

2016 AUA/SUO指南：非肌层浸润性膀胱癌的诊断和治疗

美国泌尿外科学会(AUA,American Urological Association) · 2016-04-01

2017 EAU指南：非肌层浸润性膀胱癌（Ta, T1, CIS）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2017-03-01

非肌层浸润性膀胱癌二次电切中国专家共识

中华医学会泌尿外科学分会(CUA) · 2017-08-30

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018简化版）

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-01-01

非肌层浸润性膀胱癌膀胱灌注治疗专家共识

中国泌尿外科相关专家组（统称） · 2019-01-30

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018年标准版）

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-07-30